CD19 and precursor B-cell acute lymphoblastic leukemia: Despite unprecedented successes in early phase trials of anti-CD19 CAR T cells for the treatment of relapsed/refractory B-ALL, relapses with CD19 loss occurs in a large fraction of patients [28].